- Research works
- 20 ▲ 212% vs 2013–17
- Citations
- 468 23.0 per fractional work
- Top-10% rate
- 17.2% record average 16.5%
- Open access
- 58% world 28%
Not ranked overall: Galecto (Denmark) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Who are the top researchers at Galecto (Denmark)?
Ranked on the composite score, Hans Schambye lead among researchers whose main affiliation is Galecto (Denmark).
- 1 Hans Schambye Denmark · #846,083 worldwide 73 citations · 15 works
Which keywords describe research at Galecto (Denmark)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer, Inflammation, Angiogenesis, Fibrosis, Autoimmunity, Heart Failure, Galectins and Immune Regulation.
- Tumor Regression
- Tumor Antigen
- Antigen Presentation
- Glycans
- PD-1 and PD-L1
- Cancer Therapy
- Cancer Immunotherapy
- Immune Regulation
- Galectins
- Fibrosis
- Inflammation
- Cancer
- Angiogenesis
- Autoimmunity
- Heart Failure
- Tumor Microenvironment
- Innate Immunity
- Immune Checkpoint Blockade
- Immunity
- Glycosylation
- Dendritic Cells
- Immunotherapy
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 22 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 22 words, with their numbers
- Cancer7▲ 26×7 topics
- Inflammation6▲ 14×9 topics
- Angiogenesis6▲ 75×5 topics
- Fibrosis5▲ 125×3 topics
- Autoimmunity5▲ 115×3 topics
- Galectins5▲ 1053×1 topic
- Heart Failure5▲ 50×3 topics
- Immune Regulation5▲ 171×1 topic
- Tumor Microenvironment2▲ 35×2 topics
- Cancer Immunotherapy2▲ 69×2 topics
- Innate Immunity2▲ 29×3 topics
- Cancer Therapy2▲ 14×5 topics
- Immune Checkpoint Blockade2▲ 156×1 topic
- PD-1 and PD-L12▲ 156×1 topic
- Immunity2▲ 25×2 topics
- Glycans2▲ 95×1 topic
- Glycosylation2▲ 35×1 topic
- Antigen Presentation2▲ 74×2 topics
- Dendritic Cells1▲ 61×1 topic
- Tumor Antigen1▲ 87×1 topic
- Immunotherapy1▲ 9.8×3 topics
- Tumor Regression1▲ 69×2 topics
Which research topics does Galecto (Denmark) publish most on?
By volume in 2022–2025: Galectins and Cancer Biology, Glycosylation and Glycoproteins Research, Cancer Immunotherapy and Biomarkers and Immunotherapy and Immune Responses.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Galectins and Cancer Biology Immunology 3 works
- 2 Glycosylation and Glycoproteins Research Molecular Biology 1 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 4 Immunotherapy and Immune Responses Immunology 1 works
- 5 Toxin Mechanisms and Immunotoxins Immunology 0 works
- 6 Studies on Chitinases and Chitosanases Molecular Biology 0 works
- 7 Cancer Research and Treatments Biotechnology 0 works
- 8 Brucella: diagnosis, epidemiology, treatment Small Animals 0 works
- 9 CAR-T cell therapy research Oncology 0 works
- 10 Cancer Mechanisms and Therapy Pathology and Forensic Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Galecto (Denmark)'s research output changed?
Output in 2018–2022 was 212% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Copenhagen
- University of Copenhagen
- Rigshospitalet
- Copenhagen Business School
- Copenhagen University Hospital
- Gentofte Hospital
- Bispebjerg Hospital
- Statens Serum Institut
- Novo Nordisk (Denmark)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.